CING: 460% | Cingulate Said We Received Guidance From The FDA Regarding Its Clinical Program For CTX-1301 its Lead Investigational Product Candidate For The Treatment Of ADHD. Based On This Guidance, We Expect To Submit The NA For CTX-1301 In H1 2025

LAES: 222% | SEALSQ Disclosed That Its Post-quantum Semiconductor Technology Based On Cryptographic Algorithms, Is Specifically Designed To Withstand Attacks From And Secure Cryptocurrency Transactions Against The Looming Threat Of Quantum Computing

MBOT: 67% | Microbot Medical Disclosed The Successful Completion Of Its GLP Pivotal Pre-clinical Study, Done Under The Guidelines Of FDA-required Levels Of Planning, Controlling, Monitoring, And Reporting, Using A Porcine Model